12 December 2023 - Some patients with type 2 diabetes say they are having more difficulty getting reimbursed for drugs like Ozempic as US insurers implement restrictions designed to deter doctors from prescribing the medication for weight loss.

Novo Nordisk confirmed in a recent email that it is seeing tighter health plan management of GLP-1 drugs including Ozempic and is working to minimise disruption for type 2 diabetes patients. The trend has contributed to a recent dip in US prescriptions, an executive at the Danish drugmaker said at an investor conference last month.

Read Reuters article